A Six Week Efficacy, Safety and Tolerability Study of V565 in Crohn's Disease

NCT02976129 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

125

Enrollment

INDUSTRY

Sponsor class

Conditions

Crohn's Disease

Interventions

DRUG: V565
DRUG: Placebo

Sponsor

VHsquared Ltd.